197 related articles for article (PubMed ID: 24854356)
1. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.
Takase K; Horton SC; Ganesha A; Das S; McHugh A; Emery P; Savic S; Buch MH
Ann Rheum Dis; 2014 Sep; 73(9):1695-9. PubMed ID: 24854356
[TBL] [Abstract][Full Text] [Related]
2. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
Aghdashi MA; Khadir M; Dinparasti-Saleh R
Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
[TBL] [Abstract][Full Text] [Related]
3. Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials.
Buch MH; Johnsen A; Schiff M
Clin Exp Rheumatol; 2019; 37(1):127-132. PubMed ID: 30148437
[TBL] [Abstract][Full Text] [Related]
4. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Ishikawa Y; Hashimoto M; Ito H; Tanaka M; Yukawa N; Fujii T; Yamamoto W; Mimori T; Terao C
Semin Arthritis Rheum; 2019 Oct; 49(2):204-210. PubMed ID: 30803720
[TBL] [Abstract][Full Text] [Related]
5. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
Benucci M; Saviola G; Baiardi P; Cammelli E; Manfredi M
Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
[TBL] [Abstract][Full Text] [Related]
6. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
Kvamme MK; Lie E; Uhlig T; Moger TA; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2015 Jul; 54(7):1226-35. PubMed ID: 25573840
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
[TBL] [Abstract][Full Text] [Related]
10. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
[TBL] [Abstract][Full Text] [Related]
11. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
12. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
13. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
[No Abstract] [Full Text] [Related]
14. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
[TBL] [Abstract][Full Text] [Related]
15. Association of anti-Ro/SSA antibody with response to biologics in patients with rheumatoid arthritis.
Hagiwara S; Tsuboi H; Honda F; Takahashi H; Kurata I; Ohyama A; Yagishita M; Abe S; Kurashima Y; Kaneko S; Kawaguchi H; Takahashi H; Ebe H; Yokosawa M; Asashima H; Hirota T; Umeda N; Kondo Y; Matsumoto I; Sumida T
Mod Rheumatol; 2016 Nov; 26(6):857-862. PubMed ID: 26873159
[TBL] [Abstract][Full Text] [Related]
16. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
17. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
Bacquet-Deschryver H; Jouen F; Quillard M; Ménard JF; Goëb V; Lequerré T; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
[TBL] [Abstract][Full Text] [Related]
18. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced Bullous Pemphigoid and Lupus Erythematosus Occurring under Anti-TNF-α and IL-6 Therapy in a Patient with Rheumatoid Arthritis.
Yoshikawa N; Matsubara E; Yamamoto M; Yamazaki H; Uehara M; Kamata M; Tanaka H
Intern Med; 2020 Oct; 59(20):2611-2618. PubMed ID: 32641647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]